Zobrazeno 1 - 10
of 37
pro vyhledávání: ''
Autor:
Meagan Gray, Charles M. Rowland, Michael J. McPhaul, Kenneth Cusi, Dov Shiffman, Romina Lomonaco, Srilaxmi Kalavalapalli, Fernando Bril, Diana Barb
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 106:e4360-e4371
Context Patients with nonalcoholic fatty liver disease (NAFLD) are characterized by insulin resistance and hyperinsulinism. However, insulin resistance measurements have not been shown to be good diagnostic tools to predict NAFLD in prior studies. Ob
Autor:
Andreas Peter, Hans-Ulrich Häring, Martin Heni, Corinna Dannecker, Norbert Stefan, Andreas L. Birkenfeld, Julia Hummel, Robert Wagner, Andreas Vosseler, Andreas Fritsche
Publikováno v:
J. Clin. Endocrinol. Metab. 106, 1576-1584 (2021)
The Journal of Clinical Endocrinology and Metabolism
The Journal of Clinical Endocrinology and Metabolism
Context Pharmacological lowering of low-density lipoprotein (LDL) cholesterol potently reduces cardiovascular risk while concurrently increasing type 2 diabetes risk. Objective The aim of this study was to investigate the relationship between LDL cho
Autor:
Jack C M Ng, C. Mary Schooling
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 105:e2778-e2788
Context Glucagon acts reciprocally with insulin to regular blood glucose. However, the effect of glucagon on cardiovascular disease has not been widely studied. It has been suggested that insulin may increase the risk of ischemic heart disease. Objec
Efficacy of Exenatide Plus Pioglitazone Vs Basal/Bolus Insulin in T2DM Patients With Very High HbA1c
Autor:
Osama Migahid, Muhammad A. Abdul-Ghani, Amin Jayyousi, Ralph A. DeFronzo, Mahmoud Zirie, Ayman Megahed
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 102:2162-2170
Objective To examine the efficacy and safety of combination therapy with exenatide plus pioglitazone vs basal/bolus insulin in patients with poorly controlled type 2 diabetes mellitus (T2DM) with very high hemoglobin A1c (HbA1c) (>10%) receiving sulf
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 100:E1225-E1233
Roux-en-Y gastric bypass (RYGB) is the most effective treatment for morbid obesity and resolution of diabetes. Over the last decade, it has become well accepted that this resolution of diabetes occurs before significant weight loss; however, the mech
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 100:1078-1087
Increased adiposity and insulin resistance are associated with hyperglycemia and previous studies have reported that higher glucoses are associated with lower rates of weight gain. One possible mechanism is via increased energy expenditure (EE).To as
Autor:
Massimo Pietropaolo, Ying-Jian Zhang, Lewis H. Kuller, Tyona Henderson, Susan L. Pietropaolo, Emma Barinas-Mitchell
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 91:2871-2877
Autoantibodies (AA) to glutamic acid decarboxylase (GAD65), a determinant of risk for autoimmune diabetes, have been found in up to 10% of patients with type 2 diabetes. In older adults, this marker may also serve as a determinant of risk for autoimm
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 90:1483-1488
We examined the relationships among IGF binding protein (IGFBP)-1, insulin sensitivity, and leptin in different ethnic groups (Asian Indians, Chinese, and Caucasians) using the euglycemic hyperinsulinemic clamp. Ten healthy, young and nondiabetic sub
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 90:1078-1082
Capillary recruitment in muscles, induced by insulin, has been proposed to be impaired in insulin-resistant states. To elucidate the mechanisms regulating capillary transport of insulin and glucose in type 2 diabetes, we directly calculated the perme
Autor:
Gregory L. Burke, Trevor J. Orchard, Russell P. Tracy, Joshua I. Barzilay, Richard A. Kronmal, Peter J. Savage
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 89:2852-2858
It is not known whether insulin levels, in the setting of insulin treatment, are an independent risk factor for coronary heart disease (CHD). We studied a cohort of 116 insulin-treated individuals, 65 yr or older, who were followed for 5.6-9 yr. All